← Back to Search

Treatment for Psoriasis (TARGET-DERM Trial)

N/A
Recruiting
Research Sponsored by Target PharmaSolutions, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 25 years
Awards & highlights
No Placebo-Only Group

Summary

TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

Eligible Conditions
  • Psoriasis
  • Chronic Urticaria
  • Alopecia Areata
  • Hidradenitis Suppurativa
  • Vitiligo
  • Atopic Dermatitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~25 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 25 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Characterize IMISC Treatment Regimens in Clinical Practice
Evaluate Adverse Events of IMISC and treatment in Clinical Practice
Evaluate Patient Outcomes in Clinical Practice
Secondary study objectives
Evaluate Patient Reported Outcome (PRO) measures
Evaluate outcomes related to Patient Support Programs (PSPs)
Evaluate the relationship between IMISC and comorbid medical conditions

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Find a Location

Who is running the clinical trial?

Target PharmaSolutions, Inc.Lead Sponsor
16 Previous Clinical Trials
5,651,582 Total Patients Enrolled
Laura DalfonsoStudy DirectorTarget RWE
~10000 spots leftby Dec 2050